Why is it important to conduct extractables&leachables testing on medical silicone tubing?

The Batch That Passed Every Visual Check and Still Got Rejected

A shipment of medical-grade silicone tubing arrives. Dimensions are within tolerance. Hardness matches the specification. Visual inspection is clean. The supplier even provides standard biocompatibility documentation. Yet the batch is rejected during the customer's quality audit.

The reason is not a defect anyone can see. It is the absence of extractables and leachables (E&L) data generated under conditions relevant to the actual drug-contact scenario. Material that is "safe" in a general sense is not automatically proven suitable for a specific pharmaceutical fluid, contact time, temperature, and process. That gap is exactly what E&L testing is meant to close.

Extractables vs Leachables: Two Related but Different Concepts

Extractables are compounds that can be forced out of a material under aggressive, exaggerated laboratory conditions-strong solvents, elevated temperature, extended time. The test is designed to reveal the material's maximum potential to release substances. It answers the question: "What could come out?"

Leachables are the compounds that actually migrate into a real or simulated product under conditions that approximate actual use-real drug product or placebo, realistic contact time, temperature, and surface-to-volume ratio. Leachables data answers the more practical question: "What does come out in this specific application?"

The two studies are complementary. Extractables data helps screen materials and identify potential risks early. Leachables data confirms (or rules out) those risks under conditions that matter for the final product.

Why This Testing Exists - What's Actually at Risk

Even high-purity pharmaceutical silicone tubing can contain trace residual monomers, oligomers, catalysts, or processing aids. Under prolonged contact or in the presence of certain solvents, surfactants, or active pharmaceutical ingredients, these substances may migrate at low levels into the fluid path.

At sufficiently low concentrations the risk may be negligible. At higher levels-or with highly potent or sensitive biologics-those same compounds can affect product purity, stability, or patient safety. Basic biocompatibility testing evaluates biological response to the material itself; it does not systematically identify and quantify every potential migrant or assess its toxicological relevance in the context of a finished drug product. That is the role of a properly designed E&L study.

Pharmaceutical Silicone Tubing - Why This Category Faces the Strictest Scrutiny

Pharmaceutical and bioprocessing applications place unusually high demands on contact materials. Single-use systems, bioreactor tubing, and long-duration drug-contact lines often involve:

Extended or repeated exposure

Chemically active or high-value formulations

Strict impurity limits driven by regulatory expectations for parenteral and biologic products

As a result, Pharmaceutical Silicone Tubing is routinely subjected to more rigorous E&L evaluation than many other medical devices. Manufacturers who supply this category are increasingly expected to provide application-relevant data rather than generic material certificates.

Medical Silicone HoseWhen E&L Testing Becomes Relevant Beyond Pharma

The same principles apply outside classic pharmaceutical manufacturing. Medical Silicone Hose used for prolonged fluid contact, certain disinfection protocols, or repeated exposure to aggressive cleaners can also benefit from leachables assessment. While the regulatory trigger may be different, the underlying risk-uncontrolled migration of material components-remains the same.

Surgical Silicone TubingWhy Short Contact Time Doesn't Mean Zero Risk

Surgical applications often involve relatively brief contact. That does not automatically eliminate concern. Procedures involving extracorporeal circuits, extended perfusion, or highly reactive solutions still warrant evaluation of potential migrants. Contact time is only one variable; chemistry, temperature, and surface area also matter. Assuming "it is used quickly, so leaching cannot be an issue" is an oversimplification that quality and regulatory teams increasingly reject.

What a Real E&L Study Actually Looks At

A credible extractables and leachables program is more than a single laboratory report. It typically includes three linked stages:

Test Conditions That Simulate Real (or Worst-Case) Exposure Solvents, temperature, time, and surface-to-volume ratios are chosen to either exaggerate potential extraction (extractables) or closely mimic the intended use (leachables). The more relevant the conditions, the more useful the data.

Analytical Methods Used to Detect Trace Compounds Sensitive techniques such as GC-MS, LC-MS, ICP-MS, and others are applied to identify and quantify organic and inorganic species at very low levels. Method sensitivity and coverage determine whether relevant compounds are actually found.

Toxicological Risk Assessment of Detected Substances Detected compounds are evaluated against established safety thresholds, taking into account dose, exposure route, and patient population. The goal is not merely to list substances but to determine whether they pose a meaningful risk under the intended conditions of use.

Comparison Table - Extractables Study vs Leachables Study

Common Mistakes When Evaluating Supplier E&L Documentation

Treating a biocompatibility certificate as equivalent to an E&L report

Accepting a "pass" conclusion without examining the actual test conditions

Assuming generic extractables data generated with aggressive solvents automatically applies to a specific drug formulation

Using supplier data generated on a different formulation or process without verification

Focusing only on the presence of a report rather than the completeness of the analytical and toxicological assessment

Industry Trends: Why E&L Requirements Keep Getting More Rigorous

The rapid adoption of single-use bioprocessing systems has increased the number of plastic and silicone contact surfaces in critical fluid paths. At the same time, regulatory expectations for impurity control in complex biologics continue to tighten. Together these factors have elevated E&L evaluation from a specialized concern to a routine expectation for high-risk drug-contact materials, including pharmaceutical-grade silicone tubing.

Regulatory Context - Standards and Guidance Relevant to E&L Testing

Relevant frameworks include USP chapters addressing plastic packaging systems and related materials (commonly referenced under the USP <661> family and associated guidance), as well as industry best-practice documents on extractables and leachables assessment. Specific requirements depend on the product type, route of administration, and region. Always verify the current versions of applicable standards and guidance rather than relying on outdated summaries.

How to Evaluate a Supplier's E&L Data Before You Commit

When reviewing documentation from a silicone tubing manufacturer or OEM pharmaceutical silicone tubing supplier:

Clarify whether the data represent an extractables study, a leachables study, or both

Confirm that the test conditions reasonably approximate your actual use case (or are appropriately conservative)

Request the full list of detected compounds, analytical methods, and toxicological assessment rather than a simple "compliant" statement

Ask whether the data were generated on the exact material and process intended for your product

Discuss the need for a customized study if your formulation or process differs significantly from the conditions used in the supplier's existing data

These questions help separate suppliers who treat E&L as a checkbox from those who treat it as a genuine risk-management tool.

FAQ